{"id":"cortisone-acetate","rwe":[{"pmid":"41561040","year":"2025","title":"Effects of Lenvatinib treatment for advanced differentiated thyroid cancer on cortisol deficiency.","finding":"","journal":"Frontiers in endocrinology","studyType":"Clinical Study"},{"pmid":"41411214","year":"2026","title":"Inhalation of N-Chlorotaurine Is an Effective Treatment of <italic>Aspergillus fumigatus</italic> Pneumonia in Mice.","finding":"","journal":"Journal of innate immunity","studyType":"Clinical Study"},{"pmid":"41305402","year":"2025","title":"Invariant and Diverse NKT Cells Regulate Bacterial Clearance and Pathology in Chlamydial Genital Tract Infection in Mice.","finding":"","journal":"Pathogens (Basel, Switzerland)","studyType":"Clinical Study"},{"pmid":"40913682","year":"2025","title":"Mineralocorticoid effects of fludrocortisone and hydrocortisone in primary adrenal insufficiency: EU-AIR patient data.","finding":"","journal":"Journal of endocrinological investigation","studyType":"Clinical Study"},{"pmid":"40876212","year":"2025","title":"High-throughput suspect screening of priority hormone-disrupting chemicals in megacity aquatic ecosystems using a domain-specific database framework.","finding":"","journal":"Water research","studyType":"Clinical Study"}],"_fda":{"id":"2b02919f-d84a-4c9c-8b74-173ed40b2784","set_id":"4c28ec7f-4490-4106-8472-d94c7073c306","openfda":{"nui":["N0000000209","N0000000245","N0000175552","N0000175555","N0000175570","M0003647","N0000185375","N0000175629","N0000184306","N0000185001","M0000728","M0016962","M0516536"],"upc":["0877730004505"],"unii":["S7V92P67HO","7JM57I419K","Q28R5GF371","883WKN7W8X","YHA2XLJ956","YKH834O4BH","E1UOL152H7","2E32821G6I","E4GA8884NN","27YLU75U4W","H6241UJ22B","QDL83WN8C2","269XH13919","0B4FDL9I6P","A4KL1HMZ7T"],"route":["ORAL"],"spl_id":["2b02919f-d84a-4c9c-8b74-173ed40b2784"],"brand_name":["STRESS / FATIGUE"],"spl_set_id":["4c28ec7f-4490-4106-8472-d94c7073c306"],"package_ndc":["43406-0612-1"],"product_ndc":["43406-0612"],"generic_name":["EPINEPHRINE, THYROID UNSPECIFIED,BOS TAURUS PITUITARY GLAND, ARSENIC TRIOXIDE, OYSTER SHELL CALCIUM CARBONATE CRUDE, CONIUM MACULATUM FLOWERING TOP, CORTISONE ACETATE, CROTALUS HORRIDUS HORRIDUS VENOM, IRON, STRYCHNOS NUX-VOMICA SEED, PHOSPHORIC ACID, PHOSPHORUS, SELENIUM, SEPIA OFFICINALIS JUICE, ZANTHOXYLUM AMERICANUM BARK"],"product_type":["HUMAN OTC DRUG"],"pharm_class_cs":["Catecholamines [CS]","Allergens [CS]","Plant Proteins [CS]","Seed Storage Proteins [CS]"],"pharm_class_pe":["Increased Histamine Release [PE]","Cell-mediated Immunity [PE]","Increased IgG Production [PE]"],"substance_name":["ARSENIC TRIOXIDE","BOS TAURUS PITUITARY GLAND","CONIUM MACULATUM FLOWERING TOP","CORTISONE ACETATE","CROTALUS HORRIDUS HORRIDUS VENOM","EPINEPHRINE","IRON","OYSTER SHELL CALCIUM CARBONATE, CRUDE","PHOSPHORIC ACID","PHOSPHORUS","SELENIUM","SEPIA OFFICINALIS JUICE","STRYCHNOS NUX-VOMICA SEED","THYROID, UNSPECIFIED","ZANTHOXYLUM AMERICANUM BARK"],"pharm_class_epc":["alpha-Adrenergic Agonist [EPC]","beta-Adrenergic Agonist [EPC]","Catecholamine [EPC]","Non-Standardized Plant Allergenic Extract [EPC]"],"pharm_class_moa":["Adrenergic alpha-Agonists [MoA]","Adrenergic beta-Agonists [MoA]"],"manufacturer_name":["Natural Creations, Inc."],"is_original_packager":[true]},"purpose":["Uses : Temporarily relieves symptoms of stress, fatigue, and simple nervous tension.**"],"version":"6","warnings":["WARNINGS: *Consult a physician for use in children under 12 years of age. * IF PREGNANT OR BREAST-FEEDING, ask a health care professional before use. * KEEP OUT OF THE REACH OF CHILDREN. In case of overdose (or accidental ingestion) get medical help or contact a Poison Control Center right away. * Do not use if TAMPER EVIDENT seal is broken or missing."],"questions":["Questions & Comments? Natural Creations, Inc. / Woodbine, IA 51579 / 712-647-1600"],"references":["*The letters \"HPUS\" indicate the components in this product are officially monographed in the Homeopathic Pharmacopeia of the United States. **Claims based on traditional homeopathic practice, not accepted medical evidence. Not FDA evaluated."],"effective_time":"20220303","active_ingredient":["ACTIVE INGREDIENTS (HPUS*) - equal amounts of: ​Adrenalinum 6X, Pituitary Gland 6X, Thyroidinum 6X, Arsenicum Alb 12X, Calc Carb 12X, Conium 12X, Cortisone Aceticum 12X, Crotalus Hor 12X, Ferrum Met 12X, Nux Vomica 12X, Phosphoricum Ac 12X, Phosphorus 12X, Selenium 12X Sepia 12X, Xanthoxylum 30C."],"inactive_ingredient":["Inactive Ingredients: Ethyl Alcohol USP , Purified Water."],"indications_and_usage":["Uses : Temporarily relieves symptoms of stress, fatigue, and simple nervous tension.**"],"dosage_and_administration":["Directions: Adults & children above 12 years: 10 drops orally 3 times daily, or as directed by a health care professional."],"spl_product_data_elements":["STRESS / FATIGUE Epinephrine, Thyroid Unspecified,Bos Taurus Pituitary Gland, Arsenic Trioxide, Oyster Shell Calcium Carbonate Crude, Conium Maculatum Flowering Top, Cortisone Acetate, Crotalus Horridus Horridus Venom, Iron, Strychnos Nux-Vomica Seed, Phosphoric Acid, Phosphorus, Selenium, Sepia Officinalis Juice, Zanthoxylum Americanum Bark EPINEPHRINE EPINEPHRINE THYROID, UNSPECIFIED THYROID, UNSPECIFIED BOS TAURUS PITUITARY GLAND BOS TAURUS PITUITARY GLAND ARSENIC TRIOXIDE ARSENIC CATION (3+) OYSTER SHELL CALCIUM CARBONATE, CRUDE OYSTER SHELL CALCIUM CARBONATE, CRUDE CONIUM MACULATUM FLOWERING TOP CONIUM MACULATUM FLOWERING TOP CORTISONE ACETATE CORTISONE CROTALUS HORRIDUS HORRIDUS VENOM CROTALUS HORRIDUS HORRIDUS VENOM IRON IRON STRYCHNOS NUX-VOMICA SEED STRYCHNOS NUX-VOMICA SEED PHOSPHORIC ACID PHOSPHORIC ACID PHOSPHORUS PHOSPHORUS SELENIUM SELENIUM SEPIA OFFICINALIS JUICE SEPIA OFFICINALIS JUICE ZANTHOXYLUM AMERICANUM BARK ZANTHOXYLUM AMERICANUM BARK ALCOHOL WATER"],"keep_out_of_reach_of_children":["WARNINGS: * Consult a physician for use in children under 12 years of age. * IF PREGNANT OR BREAST-FEEDING, ask a health care professional before use. * KEEP OUT OF THE REACH OF CHILDREN. In case of overdose (or accidental ingestion) get medical help or contact a Poison Control Center right away."],"package_label_principal_display_panel":["NDC: 43406-0612-1 STRESS / FATIGUE HOMEOPATHIC 1 fl oz (30 mL) 20% Alcohol UPC: 877730004505 NON GMO Logo image description"]},"tags":[{"label":"cortisone","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Corticosteroid-binding globulin","category":"target"},{"label":"SERPINA6","category":"gene"},{"label":"SHBG","category":"gene"},{"label":"NR3C1","category":"gene"},{"label":"Oral","category":"route"},{"label":"Tablet","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Established","category":"status"},{"label":"Acne vulgaris","category":"indication"},{"label":"Acquired thrombocytopenia","category":"indication"},{"label":"Acute lymphoid leukemia","category":"indication"},{"label":"Adrenal cortical hypofunction","category":"indication"},{"label":"Adrenogenital disorder","category":"indication"},{"label":"Allergic conjunctivitis","category":"indication"},{"label":"Approved 1950s","category":"decade"},{"label":"Anti-Inflammatory Agents","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"SYSTEMIC LUPUS ERYTHEMATOSUS","source":"FDA FAERS","actionTaken":"6070 reports"},{"date":"","signal":"PAIN","source":"FDA FAERS","actionTaken":"6068 reports"},{"date":"","signal":"PEMPHIGUS","source":"FDA FAERS","actionTaken":"5974 reports"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"5972 reports"},{"date":"","signal":"ALOPECIA","source":"FDA FAERS","actionTaken":"5923 reports"},{"date":"","signal":"ABDOMINAL DISCOMFORT","source":"FDA FAERS","actionTaken":"5831 reports"},{"date":"","signal":"RHEUMATOID ARTHRITIS","source":"FDA FAERS","actionTaken":"5822 reports"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"5483 reports"},{"date":"","signal":"GLOSSODYNIA","source":"FDA FAERS","actionTaken":"5394 reports"},{"date":"","signal":"SWELLING","source":"FDA FAERS","actionTaken":"5263 reports"}],"drugInteractions":[{"url":"/drug/aripiprazole","drug":"aripiprazole","action":"Monitor closely","effect":"May interact with Aripiprazole, Cortisone","source":"DrugCentral","drugSlug":"aripiprazole"},{"url":"/drug/quetiapine","drug":"quetiapine","action":"Monitor closely","effect":"May interact with Cortisone, Quetiapine Fumarate","source":"DrugCentral","drugSlug":"quetiapine"},{"url":"/drug/rifabutin","drug":"rifabutin","action":"Monitor closely","effect":"May interact with Cortisone, Rifabutin","source":"DrugCentral","drugSlug":"rifabutin"},{"url":"/drug/rifampicin","drug":"rifampicin","action":"Monitor closely","effect":"May interact with Cortisone, Rifampin","source":"DrugCentral","drugSlug":"rifampicin"},{"url":"/drug/risperidone","drug":"risperidone","action":"Monitor closely","effect":"May interact with Cortisone, Risperidone","source":"DrugCentral","drugSlug":"risperidone"},{"url":"/drug/warfarin","drug":"warfarin","action":"Monitor closely","effect":"May interact with Cortisone, Warfarin","source":"DrugCentral","drugSlug":"warfarin"}],"commonSideEffects":[],"contraindications":["Abscess of intestine","Acute tuberculosis","Anastomosis of intestine","Atrophoderma","Bacterial infection of eye","Bacterial infectious disease","Bacterial septicemia","Bilateral cataracts","Blister","Body fluid retention","Bullous myringitis","Chronic heart failure","Cirrhosis of liver","Condyloma acuminatum","Decreased respiratory function","Denuded skin","Diabetes mellitus","Disease caused by parasite","Disease of liver","Disorder of mucous membrane","Disorder of muscle","Diverticulitis of gastrointestinal tract","Duodenal ulcer disease","Epilepsy","Esophagitis"]},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=CORTISONE ACETATE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:31:43.760209+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Cortisone Acetate","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T00:31:51.054597+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:31:49.114054+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T00:31:42.877386+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CORTISONE ACETATE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:31:49.437996+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:31:42.359369+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:31:42.359401+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:31:42.359407+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T00:31:51.495711+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Glucocorticoid receptor agonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:31:51.054549+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1650/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:31:50.701109+00:00"}},"allNames":"cortone","offLabel":[],"synonyms":["cortisone acetate","cortone acetate","irisone acetate","adrenalex"],"timeline":[{"date":"1950-06-13","type":"positive","source":"DrugCentral","milestone":"FDA approval"}],"approvals":[{"date":"1950-06-13","orphan":false,"company":"","regulator":"FDA"}],"brandName":"Cortone","ecosystem":[{"indication":"Acne vulgaris","otherDrugs":[{"name":"adapalene","slug":"adapalene","company":"Galderma Labs Lp"},{"name":"ammonia","slug":"ammonia","company":""},{"name":"amphotericin B","slug":"amphotericin-b","company":"Apothecon"},{"name":"azelaic acid","slug":"azelaic-acid","company":"Allergan"}],"globalPrevalence":null},{"indication":"Acquired thrombocytopenia","otherDrugs":[{"name":"betamethasone","slug":"betamethasone","company":""},{"name":"betamethasone acetate","slug":"betamethasone-acetate","company":""},{"name":"dexamethasone","slug":"dexamethasone","company":""},{"name":"hydrocortisone","slug":"hydrocortisone","company":"Merck"}],"globalPrevalence":null},{"indication":"Acute lymphoid leukemia","otherDrugs":[{"name":"asparaginase","slug":"asparaginase","company":"Merck"},{"name":"betamethasone","slug":"betamethasone","company":""},{"name":"betamethasone acetate","slug":"betamethasone-acetate","company":""},{"name":"clofarabine","slug":"clofarabine","company":"Genzyme"}],"globalPrevalence":null},{"indication":"Adrenal cortical hypofunction","otherDrugs":[{"name":"betamethasone","slug":"betamethasone","company":""},{"name":"betamethasone acetate","slug":"betamethasone-acetate","company":""},{"name":"dexamethasone","slug":"dexamethasone","company":""},{"name":"hydrocortisone","slug":"hydrocortisone","company":"Merck"}],"globalPrevalence":null},{"indication":"Adrenogenital disorder","otherDrugs":[{"name":"betamethasone","slug":"betamethasone","company":""},{"name":"betamethasone acetate","slug":"betamethasone-acetate","company":""},{"name":"dexamethasone","slug":"dexamethasone","company":""},{"name":"fludrocortisone acetate","slug":"fludrocortisone-acetate","company":""}],"globalPrevalence":null},{"indication":"Allergic conjunctivitis","otherDrugs":[{"name":"acrivastine","slug":"acrivastine","company":"Auxilium Pharms Inc"},{"name":"alcaftadine","slug":"alcaftadine","company":"Allergan"},{"name":"alimemazine","slug":"alimemazine","company":"Allergan Herbert"},{"name":"antazoline","slug":"antazoline","company":"Novartis"}],"globalPrevalence":null},{"indication":"Allergic rhinitis","otherDrugs":[{"name":"acrivastine","slug":"acrivastine","company":"Auxilium Pharms Inc"},{"name":"alimemazine","slug":"alimemazine","company":"Allergan Herbert"},{"name":"antazoline","slug":"antazoline","company":"Novartis"},{"name":"astemizole","slug":"astemizole","company":""}],"globalPrevalence":null},{"indication":"Angioedema","otherDrugs":[{"name":"alimemazine","slug":"alimemazine","company":"Allergan Herbert"},{"name":"betamethasone","slug":"betamethasone","company":""},{"name":"betamethasone acetate","slug":"betamethasone-acetate","company":""},{"name":"dexamethasone","slug":"dexamethasone","company":""}],"globalPrevalence":200000}],"mechanism":{"target":"Corticosteroid-binding globulin","novelty":"First-in-class","targets":[{"gene":"SERPINA6","source":"DrugCentral","target":"Corticosteroid-binding globulin","protein":"Corticosteroid-binding globulin"},{"gene":"SHBG","source":"DrugCentral","target":"Sex hormone-binding globulin","protein":"Sex hormone-binding globulin"},{"gene":"NR3C1","source":"DrugCentral","target":"Glucocorticoid receptor","protein":"Glucocorticoid receptor"},{"gene":"FNTA","source":"DrugCentral","target":"Protein farnesyltransferase","protein":"Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha"},{"gene":"FNTB","source":"DrugCentral","target":"Protein farnesyltransferase","protein":"Protein farnesyltransferase subunit beta"},{"gene":"SLC47A1","source":"DrugCentral","target":"Multidrug and toxin extrusion protein 1","protein":"Multidrug and toxin extrusion protein 1"},{"gene":"KCNA1","source":"DrugCentral","target":"Potassium voltage-gated channel subfamily A member 1","protein":"Potassium voltage-gated channel subfamily A member 1"},{"gene":"ANXA1","source":"DrugCentral","target":"Annexin A1","protein":"Annexin A1"}],"modality":"Small Molecule","drugClass":"alpha-Adrenergic Agonist [EPC]","explanation":"","oneSentence":"","technicalDetail":"Cortone (CORTISONE ACETATE) is a synthetic corticosteroid that acts as an agonist to the glucocorticoid receptor, leading to the suppression of inflammatory and immune responses through the inhibition of phospholipase A2 and the subsequent reduction of prostaglandin and leukotriene synthesis."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Cortisone_acetate","title":"Cortisone acetate","extract":"Cortisone acetate is a synthetic glucocorticoid corticosteroid and corticosteroid ester which is marketed in many countries throughout the world, including in the United States, the United Kingdom, and various other European countries. It is the C21 acetate ester of cortisone, and acts as a prodrug of cortisone in the body."},"commercial":{"launchDate":"1950","_launchSource":"DrugCentral (FDA 1950-06-13, )"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/734","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=CORTISONE%20ACETATE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CORTISONE ACETATE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Cortisone_acetate","fields":["history","overview"],"source":"Wikipedia"},{"id":5,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T10:22:18.577980","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:31:52.801327+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"alclometasone dipropionate","drugSlug":"alclometasone-dipropionate","fdaApproval":"1982-12-14","genericCount":3,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"amcinonide","drugSlug":"amcinonide","fdaApproval":"1979-10-18","genericCount":4,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"auranofin","drugSlug":"auranofin","fdaApproval":"1985-05-24","patentStatus":"Unknown","relationship":"same-target"},{"drugName":"beclometasone dipropionate","drugSlug":"beclometasone-dipropionate","fdaApproval":"1976-05-12","relationship":"same-target"},{"drugName":"betamethasone","drugSlug":"betamethasone","fdaApproval":"1961-04-17","patentStatus":"Unknown","relationship":"same-target"},{"drugName":"betamethasone acetate","drugSlug":"betamethasone-acetate","fdaApproval":"1965-03-03","relationship":"same-target"},{"drugName":"betamethasone benzoate","drugSlug":"betamethasone-benzoate","fdaApproval":"","patentStatus":"Unknown","relationship":"same-target"},{"drugName":"betamethasone dipropionate","drugSlug":"betamethasone-dipropionate","fdaApproval":"1975-01-29","patentExpiry":"Aug 31, 2030","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"betamethasone phosphate","drugSlug":"betamethasone-phosphate","fdaApproval":"1965-03-03","relationship":"same-target"},{"drugName":"betamethasone valerate","drugSlug":"betamethasone-valerate","fdaApproval":"1967-09-02","genericCount":12,"patentStatus":"Off-patent — generic available","relationship":"same-target"}],"genericName":"cortisone acetate","indications":{"approved":[{"name":"Acne vulgaris","source":"DrugCentral","snomedId":88616000,"regulator":"FDA","eligibility":null},{"name":"Acquired thrombocytopenia","source":"DrugCentral","snomedId":74576004,"regulator":"FDA","eligibility":null},{"name":"Acute lymphoid leukemia","source":"DrugCentral","snomedId":91857003,"regulator":"FDA","eligibility":null},{"name":"Adrenal cortical hypofunction","source":"DrugCentral","snomedId":386584007,"regulator":"FDA","eligibility":null},{"name":"Adrenogenital disorder","source":"DrugCentral","snomedId":267395000,"regulator":"FDA","eligibility":null},{"name":"Allergic conjunctivitis","source":"DrugCentral","snomedId":473460002,"regulator":"FDA","eligibility":null},{"name":"Allergic rhinitis","source":"DrugCentral","snomedId":61582004,"regulator":"FDA","eligibility":null},{"name":"Angioedema","source":"DrugCentral","snomedId":41291007,"regulator":"FDA","eligibility":null,"globalPrevalence":200000,"prevalenceMethod":"ai-extracted","prevalenceSource":"Int Arch Allergy Immunol, 2025 (PMID:39827848)"},{"name":"Ankylosing spondylitis","source":"DrugCentral","snomedId":9631008,"regulator":"FDA","eligibility":null,"usPrevalence":null,"globalPrevalence":64000000,"prevalenceMethod":"curated","prevalenceSource":"Arthritis Care Res (Hoboken), 2016 (PMID:26713432)"},{"name":"Aphthous ulcer of mouth","source":"DrugCentral","snomedId":426965005,"regulator":"FDA","eligibility":null},{"name":"Articular gout","source":"DrugCentral","snomedId":48440001,"regulator":"FDA","usPrevalence":9200000,"globalPrevalence":41000000,"prevalenceMethod":"curated","prevalenceSource":"Lancet Rheumatology, 2023"},{"name":"Aspiration pneumonitis","source":"DrugCentral","snomedId":155597006,"regulator":"FDA","eligibility":null},{"name":"Asthma","source":"DrugCentral","snomedId":195967001,"regulator":"FDA","usPrevalence":25000000,"globalPrevalence":262000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2023"},{"name":"Atopic dermatitis","source":"DrugCentral","snomedId":24079001,"regulator":"FDA","eligibility":null,"usPrevalence":null,"globalPrevalence":204050000,"prevalenceMethod":"curated","prevalenceSource":"Br J Dermatol, 2023 (PMID:37705227)"},{"name":"Autoimmune disease","source":"DrugCentral","snomedId":85828009,"regulator":"FDA"},{"name":"Autoimmune hemolytic anemia","source":"DrugCentral","snomedId":413603009,"regulator":"FDA"},{"name":"Bacterial keratitis","source":"DrugCentral","snomedId":314557000,"regulator":"FDA","globalPrevalence":6000000,"prevalenceMethod":"ai-extracted","prevalenceSource":"Cochrane Database Syst Rev, 2025 (PMID:40728038)"},{"name":"Berylliosis","source":"DrugCentral","snomedId":8247009,"regulator":"FDA","eligibility":null},{"name":"Blepharoconjunctivitis","source":"DrugCentral","snomedId":68659002,"regulator":"FDA"},{"name":"Bursitis","source":"DrugCentral","snomedId":84017003,"regulator":"FDA"},{"name":"Cerebral edema","source":"DrugCentral","snomedId":2032001,"regulator":"FDA"},{"name":"Chronic ulcerative proctitis","source":"DrugCentral","snomedId":52231000,"regulator":"FDA"},{"name":"Congenital adrenal hyperplasia","source":"DrugCentral","snomedId":237751000,"regulator":"FDA","eligibility":null,"prevalenceClass":"1-9 / 100 000","globalPrevalence":800000,"prevalenceMethod":"orphanet","prevalenceSource":"Orphanet (European Medicines Agency 2018[INST])"},{"name":"Congenital hypoplastic anemia","source":"DrugCentral","snomedId":88854002,"regulator":"FDA"},{"name":"Contact dermatitis","source":"DrugCentral","snomedId":40275004,"regulator":"FDA","eligibility":null,"usPrevalence":null,"globalPrevalence":324000000,"prevalenceMethod":"curated","prevalenceSource":"Contact Dermatitis, 2025 (PMID:40107276)"},{"name":"Corneal abrasion","source":"DrugCentral","snomedId":85848002,"regulator":"FDA"},{"name":"Corneal ulcer","source":"DrugCentral","snomedId":91514001,"regulator":"FDA"},{"name":"Crohn's disease","source":"DrugCentral","snomedId":34000006,"regulator":"FDA","usPrevalence":780000,"globalPrevalence":5000000,"prevalenceMethod":"curated","prevalenceSource":"Lancet Gastroenterology, 2023"},{"name":"Cyclitis","source":"DrugCentral","snomedId":17657000,"regulator":"FDA","prevalenceClass":"1-9 / 1 000 000","globalPrevalence":40000,"prevalenceMethod":"orphanet","prevalenceSource":"Orphanet (9088407[PMID])"},{"name":"Dermatitis herpetiformis","source":"DrugCentral","snomedId":111196000,"regulator":"FDA","prevalenceClass":"1-5 / 10 000","globalPrevalence":2160000,"prevalenceMethod":"orphanet","prevalenceSource":"Orphanet ([EXPERT])"},{"name":"Diagnostic Test for Cushing's Syndrome","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Discoid lupus erythematosus","source":"DrugCentral","snomedId":200938002,"regulator":"FDA","usPrevalence":null,"globalPrevalence":2400000,"prevalenceMethod":"curated","prevalenceSource":"Orphanet (ORPHANET)"},{"name":"Disorder of eye","source":"DrugCentral","snomedId":371405004,"regulator":"FDA"},{"name":"Disorder of musculoskeletal system","source":"DrugCentral","snomedId":928000,"regulator":"FDA"},{"name":"Disorder of skin","source":"DrugCentral","snomedId":95320005,"regulator":"FDA"},{"name":"Edema of larynx","source":"DrugCentral","snomedId":51599000,"regulator":"FDA"},{"name":"Epicondylitis","source":"DrugCentral","snomedId":73583000,"regulator":"FDA","eligibility":null},{"name":"Eruption of skin","source":"DrugCentral","snomedId":271807003,"regulator":"FDA"},{"name":"Erythema multiforme","source":"DrugCentral","snomedId":36715001,"regulator":"FDA"},{"name":"Erythroblastic Anemia","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Erythroderma","source":"DrugCentral","snomedId":399992009,"regulator":"FDA"},{"name":"Follicular non-Hodgkin's lymphoma","source":"DrugCentral","snomedId":308121000,"regulator":"FDA"},{"name":"Gingival Disorders","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Granuloma annulare","source":"DrugCentral","snomedId":65508009,"regulator":"FDA"},{"name":"Hemorrhoids","source":"DrugCentral","snomedId":70153002,"regulator":"FDA"},{"name":"Herpes zoster keratitis","source":"DrugCentral","snomedId":397573005,"regulator":"FDA"},{"name":"Hodgkin's disease","source":"DrugCentral","snomedId":118599009,"regulator":"FDA"},{"name":"Humoral hypercalcemia of malignancy","source":"DrugCentral","snomedId":47709007,"regulator":"FDA"},{"name":"Idiopathic thrombocytopenic purpura","source":"DrugCentral","snomedId":32273002,"regulator":"FDA","eligibility":null},{"name":"Infection by larvae of Trichinella spiralis","source":"DrugCentral","snomedId":88264003,"regulator":"FDA"},{"name":"Infective blepharitis","source":"DrugCentral","snomedId":312219000,"regulator":"FDA"},{"name":"Infective otitis externa","source":"DrugCentral","snomedId":86981007,"regulator":"FDA"},{"name":"Inflammatory bowel disease","source":"DrugCentral","snomedId":24526004,"regulator":"FDA"},{"name":"Inflammatory dermatosis","source":"DrugCentral","snomedId":703938007,"regulator":"FDA"},{"name":"Iridocyclitis","source":"DrugCentral","snomedId":77971008,"regulator":"FDA","usPrevalence":null,"globalPrevalence":40000,"prevalenceMethod":"curated","prevalenceSource":"Orphanet (9088407[PMID])"},{"name":"Iritis","source":"DrugCentral","snomedId":65074000,"regulator":"FDA"},{"name":"Itching of ear","source":"DrugCentral","snomedId":699392007,"regulator":"FDA"},{"name":"Juvenile rheumatoid arthritis","source":"DrugCentral","snomedId":410795001,"regulator":"FDA","usPrevalence":1500000,"globalPrevalence":18000000,"prevalenceMethod":"curated","prevalenceSource":"Lancet Rheumatology, 2023"},{"name":"Keratitis","source":"DrugCentral","snomedId":5888003,"regulator":"FDA","eligibility":null,"usPrevalence":null,"globalPrevalence":6000000,"prevalenceMethod":"curated","prevalenceSource":"Cochrane Database Syst Rev, 2025 (PMID:40728038)"},{"name":"Lichen simplex chronicus","source":"DrugCentral","snomedId":53891004,"regulator":"FDA"},{"name":"Löffler's syndrome","source":"DrugCentral","snomedId":64936001,"regulator":"FDA"},{"name":"Malignant otitis externa due to Pseudomonas aeruginosa","source":"DrugCentral","snomedId":232230009,"regulator":"FDA"},{"name":"Mastoidectomy Cavity Infections","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Miliary tuberculosis","source":"DrugCentral","snomedId":47604008,"regulator":"FDA","prevalenceClass":"1-5 / 10 000","globalPrevalence":1280000,"prevalenceMethod":"orphanet","prevalenceSource":"Orphanet (European Medicines Agency 2018[INST])"},{"name":"Minor Bacterial Skin Infections","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Multiple sclerosis","source":"DrugCentral","snomedId":24700007,"regulator":"FDA"},{"name":"Mycosis fungoides","source":"DrugCentral","snomedId":118618005,"regulator":"FDA","eligibility":null},{"name":"Nephrotic syndrome","source":"DrugCentral","snomedId":52254009,"regulator":"FDA","eligibility":null,"prevalenceClass":"1-9 / 1 000 000","globalPrevalence":8800,"prevalenceMethod":"orphanet","prevalenceSource":"Orphanet ([EXPERT]_17162528[PMID])"},{"name":"Non-Hodgkin's lymphoma","source":"DrugCentral","snomedId":118601006,"regulator":"FDA"},{"name":"Otitis externa","source":"DrugCentral","snomedId":3135009,"regulator":"FDA"},{"name":"Pemphigus","source":"DrugCentral","snomedId":65172003,"regulator":"FDA","eligibility":null,"prevalenceClass":"1-5 / 10 000","globalPrevalence":1440000,"prevalenceMethod":"orphanet","prevalenceSource":"Orphanet (European Medicines Agency[INST])"},{"name":"Plaque psoriasis","source":"DrugCentral","snomedId":200965009,"regulator":"FDA","usPrevalence":7500000,"globalPrevalence":125000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2023"},{"name":"Post traumatic osteoarthritis","source":"DrugCentral","snomedId":699262001,"regulator":"FDA","usPrevalence":null,"globalPrevalence":655000000,"prevalenceMethod":"curated","prevalenceSource":"Arthritis Res Ther, 2023 (PMID:36991481)"},{"name":"Post-Op Ocular Inflammation","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Primary adrenocortical insufficiency","source":"DrugCentral","snomedId":373662000,"regulator":"FDA"},{"name":"Primary cutaneous T-cell lymphoma","source":"DrugCentral","snomedId":400122007,"regulator":"FDA"},{"name":"Proctitis","source":"DrugCentral","snomedId":3951002,"regulator":"FDA","prevalenceClass":"1-5 / 10 000","globalPrevalence":2800000,"prevalenceMethod":"orphanet","prevalenceSource":"Orphanet (European Medicines Agency[INST])"},{"name":"Pruritus ani","source":"DrugCentral","snomedId":90446007,"regulator":"FDA"},{"name":"Pruritus of genital organs","source":"DrugCentral","snomedId":267802000,"regulator":"FDA"},{"name":"Psoriasis","source":"DrugCentral","snomedId":9014002,"regulator":"FDA","usPrevalence":7500000,"globalPrevalence":125000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2023"},{"name":"Psoriasis with arthropathy","source":"DrugCentral","snomedId":33339001,"regulator":"FDA","usPrevalence":7500000,"globalPrevalence":125000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2023"},{"name":"Punctate keratopathy","source":"DrugCentral","snomedId":246936005,"regulator":"FDA"},{"name":"Recurrent herpes simplex labialis","source":"DrugCentral","snomedId":402892009,"regulator":"FDA"},{"name":"Rheumatic heart disease","source":"DrugCentral","snomedId":23685000,"regulator":"FDA"},{"name":"Rheumatoid arthritis","source":"DrugCentral","snomedId":69896004,"regulator":"FDA","eligibility":"juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy)","usPrevalence":1500000,"globalPrevalence":18000000,"prevalenceMethod":"curated","prevalenceSource":"Lancet Rheumatology, 2023"},{"name":"Rosacea","source":"DrugCentral","snomedId":398909004,"regulator":"FDA","globalPrevalence":434000000,"prevalenceMethod":"ai-extracted","prevalenceSource":"Br J Dermatol, 2018 (PMID:29478264)"},{"name":"Sarcoidosis","source":"DrugCentral","snomedId":31541009,"regulator":"FDA"},{"name":"Scalp psoriasis","source":"DrugCentral","snomedId":238608008,"regulator":"FDA","usPrevalence":7500000,"globalPrevalence":125000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2023"},{"name":"Seborrheic dermatitis","source":"DrugCentral","snomedId":50563003,"regulator":"FDA"},{"name":"Severe adrenal insufficiency","source":"DrugCentral","snomedId":24867002,"regulator":"FDA"},{"name":"Staphylococcus Aureus Otitis Externa","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Superficial Ocular Infection","source":"DrugCentral","snomedId":"","regulator":"FDA","usPrevalence":null,"globalPrevalence":6000000,"prevalenceMethod":"curated","prevalenceSource":"Cochrane Database Syst Rev, 2025 (PMID:40728038)"},{"name":"Synovitis","source":"DrugCentral","snomedId":416209007,"regulator":"FDA"},{"name":"Synovitis due to Osteoarthritis","source":"DrugCentral","snomedId":"","regulator":"FDA","usPrevalence":null,"globalPrevalence":655000000,"prevalenceMethod":"curated","prevalenceSource":"Arthritis Res Ther, 2023 (PMID:36991481)"},{"name":"Systemic Dermatomyositis","source":"DrugCentral","snomedId":"","regulator":"FDA","prevalenceClass":"1-9 / 100 000","globalPrevalence":602496,"prevalenceMethod":"orphanet","prevalenceSource":"Orphanet (36581896[PMID]_ORPHANET)"},{"name":"Systemic lupus erythematosus","source":"DrugCentral","snomedId":55464009,"regulator":"FDA","eligibility":null,"usPrevalence":null,"globalPrevalence":3496000,"prevalenceMethod":"curated","prevalenceSource":"Orphanet (36241363[PMID])"},{"name":"Tendinitis","source":"DrugCentral","snomedId":34840004,"regulator":"FDA"},{"name":"Tenosynovitis","source":"DrugCentral","snomedId":67801009,"regulator":"FDA"},{"name":"Thyroiditis","source":"DrugCentral","snomedId":82119001,"regulator":"FDA"},{"name":"Tinea corporis","source":"DrugCentral","snomedId":84849002,"regulator":"FDA"},{"name":"Tinea cruris","source":"DrugCentral","snomedId":399029005,"regulator":"FDA"},{"name":"Tinea pedis","source":"DrugCentral","snomedId":6020002,"regulator":"FDA","usPrevalence":null,"globalPrevalence":640000000,"prevalenceMethod":"curated","prevalenceSource":"BMC Public Health, 2025 (PMID:40993673)"},{"name":"Transfusion Reaction Urticaria","source":"DrugCentral","snomedId":"","regulator":"FDA","usPrevalence":null,"globalPrevalence":68000000,"prevalenceMethod":"curated","prevalenceSource":"Allergy, 2020 (PMID:31494963)"},{"name":"Transfusion reaction due to serum protein reaction","source":"DrugCentral","snomedId":72284000,"regulator":"FDA"},{"name":"Transplanted organ rejection","source":"DrugCentral","snomedId":213148006,"regulator":"FDA"},{"name":"Ulcerative colitis","source":"DrugCentral","snomedId":64766004,"regulator":"FDA","eligibility":null,"usPrevalence":900000,"globalPrevalence":5000000,"prevalenceMethod":"curated","prevalenceSource":"Lancet Gastroenterology, 2023"},{"name":"Uveitis","source":"DrugCentral","snomedId":128473001,"regulator":"FDA"}],"offLabel":[{"name":"Adrenoleukodystrophy","source":"DrugCentral","drugName":"CORTISONE ACETATE","evidenceCount":2,"evidenceLevel":"emerging"},{"name":"Allergic otitis externa","source":"DrugCentral","drugName":"CORTISONE ACETATE"},{"name":"Bronchitis","source":"DrugCentral","drugName":"CORTISONE ACETATE","evidenceCount":54,"evidenceLevel":"strong"},{"name":"Carditis","source":"DrugCentral","drugName":"CORTISONE ACETATE","evidenceCount":100,"evidenceLevel":"strong"},{"name":"Celiac disease","source":"DrugCentral","drugName":"CORTISONE ACETATE","evidenceCount":30,"evidenceLevel":"moderate"},{"name":"Chronic hepatitis","source":"DrugCentral","drugName":"CORTISONE ACETATE","evidenceCount":50,"evidenceLevel":"moderate"},{"name":"Chronic obstructive lung disease","source":"DrugCentral","drugName":"CORTISONE ACETATE","evidenceCount":44,"evidenceLevel":"moderate"},{"name":"Chronic purulent otitis media","source":"DrugCentral","drugName":"CORTISONE ACETATE","evidenceCount":3,"evidenceLevel":"emerging"},{"name":"Congenital Pituitary Hypoplasia","source":"DrugCentral","drugName":"CORTISONE ACETATE","evidenceCount":2,"evidenceLevel":"emerging"},{"name":"Eczema","source":"DrugCentral","drugName":"CORTISONE ACETATE"},{"name":"Giant cell arteritis","source":"DrugCentral","drugName":"CORTISONE ACETATE"},{"name":"Hepatic necrosis","source":"DrugCentral","drugName":"CORTISONE ACETATE"},{"name":"Hypercalcemia associated with Sarcoidosis","source":"DrugCentral","drugName":"CORTISONE ACETATE"},{"name":"Itching of skin","source":"DrugCentral","drugName":"CORTISONE ACETATE"},{"name":"Multiple myeloma","source":"DrugCentral","drugName":"CORTISONE ACETATE"},{"name":"Nasal polyp","source":"DrugCentral","drugName":"CORTISONE ACETATE"},{"name":"Neonatal Bronchopulmonary Dysplasia","source":"DrugCentral","drugName":"CORTISONE ACETATE"},{"name":"Orthostatic hypotension","source":"DrugCentral","drugName":"CORTISONE ACETATE"},{"name":"Otitis Externa Eczema","source":"DrugCentral","drugName":"CORTISONE ACETATE"},{"name":"Otitis Externa Seborrhea","source":"DrugCentral","drugName":"CORTISONE ACETATE"},{"name":"Pemphigoid","source":"DrugCentral","drugName":"CORTISONE ACETATE"},{"name":"Pericarditis","source":"DrugCentral","drugName":"CORTISONE ACETATE"},{"name":"Pityriasis simplex","source":"DrugCentral","drugName":"CORTISONE ACETATE"},{"name":"Polyarteritis nodosa","source":"DrugCentral","drugName":"CORTISONE ACETATE"},{"name":"Polymyalgia rheumatica","source":"DrugCentral","drugName":"CORTISONE ACETATE"},{"name":"Pseudogout","source":"DrugCentral","drugName":"CORTISONE ACETATE"},{"name":"Respiratory distress syndrome in the newborn","source":"DrugCentral","drugName":"CORTISONE ACETATE"},{"name":"Rheumatic fever","source":"DrugCentral","drugName":"CORTISONE ACETATE"},{"name":"Vasculitis","source":"DrugCentral","drugName":"CORTISONE ACETATE"},{"name":"West syndrome","source":"DrugCentral","drugName":"CORTISONE ACETATE"}],"pipeline":[]},"currentOwner":"Merck","drugCategory":"established","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"alclometasone-dipropionate","brandName":"alclometasone dipropionate","genericName":"alclometasone dipropionate","approvalYear":"1982","relationship":"same-target"},{"drugId":"amcinonide","brandName":"amcinonide","genericName":"amcinonide","approvalYear":"1979","relationship":"same-target"},{"drugId":"auranofin","brandName":"auranofin","genericName":"auranofin","approvalYear":"1985","relationship":"same-target"},{"drugId":"beclometasone-dipropionate","brandName":"beclometasone dipropionate","genericName":"beclometasone dipropionate","approvalYear":"1976","relationship":"same-target"},{"drugId":"betamethasone","brandName":"betamethasone","genericName":"betamethasone","approvalYear":"1961","relationship":"same-target"},{"drugId":"betamethasone-acetate","brandName":"betamethasone acetate","genericName":"betamethasone acetate","approvalYear":"1965","relationship":"same-target"},{"drugId":"betamethasone-benzoate","brandName":"betamethasone benzoate","genericName":"betamethasone benzoate","approvalYear":"","relationship":"same-target"},{"drugId":"betamethasone-dipropionate","brandName":"betamethasone dipropionate","genericName":"betamethasone dipropionate","approvalYear":"1975","relationship":"same-target"},{"drugId":"betamethasone-phosphate","brandName":"betamethasone phosphate","genericName":"betamethasone phosphate","approvalYear":"1965","relationship":"same-target"},{"drugId":"betamethasone-valerate","brandName":"betamethasone valerate","genericName":"betamethasone valerate","approvalYear":"1967","relationship":"same-target"}],"trialDetails":[{"nctId":"NCT04759586","phase":"PHASE3","title":"Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-10-05","conditions":["Primary Mediastinal Large B-Cell Lymphoma"],"enrollment":244,"completionDate":"2026-12-31"},{"nctId":"NCT05837286","phase":"NA","title":"Conservative Treatment of Trigger Finger","status":"RECRUITING","sponsor":"Cedars-Sinai Medical Center","startDate":"2023-08-01","conditions":["Hand Injuries","Trigger Finger"],"enrollment":146,"completionDate":"2026-05-31"},{"nctId":"NCT06317662","phase":"PHASE2","title":"Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-06-05","conditions":["Acute Leukemia of Ambiguous Lineage","B Acute Lymphoblastic Leukemia"],"enrollment":153,"completionDate":"2028-12-31"},{"nctId":"NCT03914625","phase":"PHASE3","title":"A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-03","conditions":["B Acute Lymphoblastic Leukemia","B Lymphoblastic Lymphoma","Down Syndrome"],"enrollment":6720,"completionDate":"2027-09-30"},{"nctId":"NCT04301076","phase":"PHASE1","title":"Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment (\"EPOCH\") for Adult T-Cell Leukemia-Lymphoma (ATLL)","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2021-08-31","conditions":["Acute Adult T-Cell Leukemia/Lymphoma","Adult T-Cell Leukemia/Lymphoma","Chronic Adult T-Cell Leukemia/Lymphoma","HTLV-1 Infection"],"enrollment":30,"completionDate":"2027-06-30"},{"nctId":"NCT02166463","phase":"PHASE3","title":"Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-03-19","conditions":["Ann Arbor Stage IIB Hodgkin Lymphoma","Ann Arbor Stage IIIB Hodgkin Lymphoma","Ann Arbor Stage IVA Hodgkin Lymphoma","Ann Arbor Stage IVB Hodgkin Lymphoma","Childhood Hodgkin Lymphoma","Classic Hodgkin Lymphoma"],"enrollment":600,"completionDate":"2026-10-03"},{"nctId":"NCT05896839","phase":"PHASE1,PHASE2","title":"Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-07-24","conditions":["Clinical Stage III Cutaneous Melanoma AJCC v8","Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8","Clinical Stage IV Cutaneous Melanoma AJCC v8","Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8","Metastatic Basal Cell Carcinoma","Metastatic Carcinoma in the Skin","Metastatic Melanoma","Metastatic Merkel Cell Carcinoma","Metastatic Skin Squamous Cell Carcinoma","Unresectable Basal Cell Carcinoma","Unresectable Melanoma","Unresectable Merkel Cell Carcinoma","Unresectable Skin Squamous Cell Carcinoma"],"enrollment":16,"completionDate":"2027-01-31"},{"nctId":"NCT00792948","phase":"PHASE2","title":"Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2009-09-01","conditions":["Acute Lymphoblastic Leukemia","Adult B Acute Lymphoblastic Leukemia","Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","Adult L1 Acute Lymphoblastic Leukemia","Adult L2 Acute Lymphoblastic Leukemia","Adult T Acute Lymphoblastic Leukemia","Recurrent Adult Acute Lymphoblastic Leukemia"],"enrollment":97,"completionDate":"2027-01-06"},{"nctId":"NCT03269669","phase":"PHASE2","title":"Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-01-23","conditions":["Grade 1 Follicular Lymphoma","Grade 2 Follicular Lymphoma","Grade 3a Follicular Lymphoma","Recurrent Follicular Lymphoma","Refractory Follicular Lymphoma"],"enrollment":73,"completionDate":"2027-01-21"},{"nctId":"NCT03984448","phase":"PHASE2,PHASE3","title":"Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-10-22","conditions":["Diffuse Large B-Cell Lymphoma","Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","Double-Expressor Lymphoma","EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements","High Grade B-Cell Lymphoma, Not Otherwise Specified","Neoplastic Cells With Double Expression of MYC and BCL2 Proteins Present","Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma"],"enrollment":363,"completionDate":"2028-04-01"},{"nctId":"NCT06649812","phase":"PHASE2","title":"Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-10-07","conditions":["High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements","Recurrent Diffuse Large B-Cell Lymphoma","Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type","Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements","Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements","Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified","Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma","Refractory Diffuse Large B-Cell Lymphoma","Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type","Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements","Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements","Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified","Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma"],"enrollment":120,"completionDate":"2027-09-01"},{"nctId":"NCT04530565","phase":"PHASE3","title":"Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-01-25","conditions":["B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1"],"enrollment":348,"completionDate":"2028-07-01"},{"nctId":"NCT05675410","phase":"PHASE3","title":"A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-05-11","conditions":["Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8"],"enrollment":1875,"completionDate":"2031-04-28"},{"nctId":"NCT01856192","phase":"PHASE2","title":"Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2013-08-27","conditions":["Ann Arbor Stage II Diffuse Large B-Cell Lymphoma","Ann Arbor Stage III Diffuse Large B-Cell Lymphoma","Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma"],"enrollment":349,"completionDate":"2026-12-31"},{"nctId":"NCT07444710","phase":"PHASE1","title":"Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-08-20","conditions":["Ann Arbor Stage II Mantle Cell Lymphoma","Ann Arbor Stage III Mantle Cell Lymphoma","Ann Arbor Stage IV Mantle Cell Lymphoma"],"enrollment":16,"completionDate":"2027-09-01"},{"nctId":"NCT02143414","phase":"PHASE2","title":"Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-06-30","conditions":["Acute Lymphoblastic Leukemia","B Acute Lymphoblastic Leukemia","B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","Recurrent Acute Lymphoblastic Leukemia","Refractory Acute Lymphoblastic Leukemia"],"enrollment":53,"completionDate":"2027-01-26"},{"nctId":"NCT05845125","phase":"PHASE4","title":"Evolution of Post-Stroke Shoulder Pain With a Capsular Pattern With Physiotherapy Alone Versus Coupled With Mild Arthrographic Distension With Cortisone","status":"TERMINATED","sponsor":"Claire Bourgeois","startDate":"2023-05-21","conditions":["Shoulder Pain"],"enrollment":50,"completionDate":"2024-05-21"},{"nctId":"NCT07224100","phase":"PHASE2","title":"Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma","status":"RECRUITING","sponsor":"University of Washington","startDate":"2026-04-15","conditions":["B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","B Lymphoblastic Leukemia/Lymphoma With t(9;22)(q34.1;q11.2); BCR-ABL1","Lymphoblastic Lymphoma"],"enrollment":33,"completionDate":"2028-07-31"},{"nctId":"NCT04799275","phase":"PHASE2,PHASE3","title":"Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2021-05-20","conditions":["Ann Arbor Stage III Diffuse Large B-Cell Lymphoma","Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma","Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma","Diffuse Large B-Cell Lymphoma Activated B-Cell Type","Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation","Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type","Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","Grade 3b Follicular Lymphoma","HHV8-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements","High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements","High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements","High Grade B-Cell Lymphoma, Not Otherwise Specified","Intravascular Large B-Cell Lymphoma","Lymphoplasmacytic Lymphoma","Nodular Lymphocyte Predominant B-Cell Lymphoma","Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type","T-Cell/Histiocyte-Rich Large B-Cell Lymphoma","Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma","Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma"],"enrollment":422,"completionDate":"2027-03-01"},{"nctId":"NCT07255248","phase":"PHASE4","title":"Hoffa's Fat Pad Impingement (HFPI)","status":"RECRUITING","sponsor":"Boston Children's Hospital","startDate":"2026-03-01","conditions":["Hoffa's Fat Pad Impingement"],"enrollment":62,"completionDate":"2028-01-02"},{"nctId":"NCT03360721","phase":"PHASE2","title":"Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-03-06","conditions":["Castration-Resistant Prostate Carcinoma","Prostate Adenocarcinoma Without Neuroendocrine Differentiation","Stage IV Prostate Cancer AJCC v8","Stage IVA Prostate Cancer AJCC v8","Stage IVB Prostate Cancer AJCC v8"],"enrollment":7,"completionDate":"2026-03-12"},{"nctId":"NCT06124157","phase":"PHASE3","title":"A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-05-30","conditions":["B Acute Lymphoblastic Leukemia"],"enrollment":222,"completionDate":"2030-12-01"},{"nctId":"NCT06738368","phase":"PHASE2","title":"Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"University of Washington","startDate":"2026-04-01","conditions":["B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative","T Acute Lymphoblastic Leukemia"],"enrollment":30,"completionDate":"2028-07-30"},{"nctId":"NCT06173362","phase":"PHASE2","title":"Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer","status":"RECRUITING","sponsor":"University of California, Davis","startDate":"2023-11-09","conditions":["Advanced Prostate Adenocarcinoma","Stage III Prostate Cancer AJCC v8","Stage IV Prostate Cancer AJCC v8"],"enrollment":75,"completionDate":"2027-05"},{"nctId":"NCT05453500","phase":"PHASE2","title":"Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"University of Washington","startDate":"2023-03-27","conditions":["B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative"],"enrollment":30,"completionDate":"2031-05-01"},{"nctId":"NCT05292664","phase":"PHASE1","title":"Venetoclax Basket Trial for High Risk Hematologic Malignancies","status":"RECRUITING","sponsor":"Andrew E. Place, MD","startDate":"2023-03-29","conditions":["Myelodysplastic Syndromes, de Novo","Myelodysplastic Syndromes, Secondary","Myelodysplastic Syndromes, Previously Treated","Treatment-Related Acute Myeloid Leukemia","Therapy-Related Myelodysplastic Syndrome","Acute Lymphoblastic Leukemia, in Relapse","Acute Lymphoblastic Leukemia With Failed Remission","Lymphoblastic Lymphoma, in Relapse","Lymphoblastic Lymphoma, Refractory","Acute Leukemia of Ambiguous Lineage in Relapse","Acute Leukemia of Ambiguous Lineage"],"enrollment":30,"completionDate":"2030-07-02"},{"nctId":"NCT03819296","phase":"PHASE1","title":"Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-02-21","conditions":["Clinical Stage 0 Cutaneous Melanoma AJCC v8","Clinical Stage I Cutaneous Melanoma AJCC v8","Clinical Stage IA Cutaneous Melanoma AJCC v8","Clinical Stage IB Cutaneous Melanoma AJCC v8","Clinical Stage II Cutaneous Melanoma AJCC v8","Clinical Stage IIA Cutaneous Melanoma AJCC v8","Clinical Stage IIB Cutaneous Melanoma AJCC v8","Clinical Stage IIC Cutaneous Melanoma AJCC v8","Clinical Stage III Cutaneous Melanoma AJCC v8","Clinical Stage IV Cutaneous Melanoma AJCC v8","Colitis","Lung Non-Small Cell Carcinoma","Malignant Genitourinary System Neoplasm","Malignant Solid Neoplasm","Pathologic Stage 0 Cutaneous Melanoma AJCC v8","Pathologic Stage I Cutaneous Melanoma AJCC v8","Pathologic Stage IA Cutaneous Melanoma AJCC v8","Pathologic Stage IB Cutaneous Melanoma AJCC v8","Pathologic Stage II Cutaneous Melanoma AJCC v8","Pathologic Stage IIA Cutaneous Melanoma AJCC v8","Pathologic Stage IIB Cutaneous Melanoma AJCC v8","Pathologic Stage IIC Cutaneous Melanoma AJCC v8","Pathologic Stage III Cutaneous Melanoma AJCC v8","Pathologic Stage IIIA Cutaneous Melanoma AJCC v8","Pathologic Stage IIIB Cutaneous Melanoma AJCC v8","Pathologic Stage IIIC Cutaneous Melanoma AJCC v8","Pathologic Stage IIID Cutaneous Melanoma AJCC v8","Pathologic Stage IV Cutaneous Melanoma AJCC v8","Stage 0 Lung Cancer AJCC v8","Stage I Lung Cancer AJCC v8","Stage IA1 Lung Cancer AJCC v8","Stage IA2 Lung Cancer AJCC v8","Stage IA3 Lung Cancer AJCC v8","Stage IB Lung Cancer AJCC v8","Stage II Lung Cancer AJCC v8","Stage IIA Lung Cancer AJCC v8","Stage IIB Lung Cancer AJCC v8","Stage III Lung Cancer AJCC v8","Stage IIIA Lung Cancer AJCC v8","Stage IIIB Lung Cancer AJCC v8","Stage IIIC Lung Cancer AJCC v8","Stage IV Lung Cancer AJCC v8","Stage IVA Lung Cancer AJCC v8","Stage IVB Lung Cancer AJCC v8"],"enrollment":800,"completionDate":"2026-10-31"},{"nctId":"NCT03959085","phase":"PHASE3","title":"Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2019-10-31","conditions":["B Acute Lymphoblastic Leukemia","B Lymphoblastic Lymphoma","Central Nervous System Leukemia","Mixed Phenotype Acute Leukemia","Testicular Leukemia"],"enrollment":5951,"completionDate":"2032-03-31"},{"nctId":"NCT02703623","phase":"PHASE2","title":"Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-05-18","conditions":["Castration Levels of Testosterone","Castration-Resistant Prostate Carcinoma","Metastatic Prostate Carcinoma","PSA Progression","Stage IV Prostate Adenocarcinoma AJCC v7"],"enrollment":196,"completionDate":"2028-03-31"},{"nctId":"NCT05157971","phase":"PHASE1","title":"Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2022-03-17","conditions":["B Acute Lymphoblastic Leukemia","Ph-Like Acute Lymphoblastic Leukemia"],"enrollment":24,"completionDate":"2026-05-12"},{"nctId":"NCT04216524","phase":"PHASE2","title":"Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-05-29","conditions":["Blastic Plasmacytoid Dendritic Cell Neoplasm"],"enrollment":40,"completionDate":"2026-12-31"},{"nctId":"NCT00602641","phase":"PHASE3","title":"Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2008-02-29","conditions":["Multiple Myeloma"],"enrollment":306,"completionDate":"2026-02-22"},{"nctId":"NCT04231877","phase":"PHASE1","title":"Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma","status":"RECRUITING","sponsor":"University of Washington","startDate":"2020-10-27","conditions":["Aggressive Non-Hodgkin Lymphoma","ALK-Positive Large B-Cell Lymphoma","Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements","High Grade B-Cell Lymphoma, Not Otherwise Specified","Primary Mediastinal Large B-Cell Lymphoma","T-Cell/Histiocyte-Rich Large B-Cell Lymphoma","Gray-Zone Lymphoma"],"enrollment":56,"completionDate":"2031-12-01"},{"nctId":"NCT00716066","phase":"PHASE2","title":"Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2008-06","conditions":["Autoimmune Disease","Neurologic Autoimmune Disease","Autologous Transplant Autoimmune","Multiple Sclerosis Transplant","MS Stem Cell Transplant","Multiple Sclerosis Stem Cell Transplant","Stiff Person Syndrome","HCT for Neurologic Autoimmune Disorders","CIDP Transplant","Myasthenia Gravis Transplant","Autoimmune Nervous System Disorder","Central Nervous System Vasculitis","Cerebellar Degeneration","Chronic Inflammatory Demyelinating Polyneuropathy","Lambert Eaton Myasthenic Syndrome","Myasthenia Gravis","Neuromyelitis Optica","Opsoclonus Myoclonus Syndrome","Rasmussen Subacute Encephalitis"],"enrollment":53,"completionDate":"2030-01-31"},{"nctId":"NCT06650579","phase":"PHASE3","title":"REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-01-31","conditions":["Recurrent Prostate Carcinoma","Stage III Prostate Cancer AJCC v8","Stage IVA Prostate Cancer AJCC v8"],"enrollment":72,"completionDate":"2029-07-01"},{"nctId":"NCT02522715","phase":"PHASE1,PHASE2","title":"Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2015-08-13","conditions":["Castration-Resistant Prostate Carcinoma","Metastatic Prostate Carcinoma","Recurrent Prostate Carcinoma","Stage IV Prostate Cancer AJCC v7"],"enrollment":37,"completionDate":"2027-01-01"},{"nctId":"NCT03007147","phase":"PHASE3","title":"Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2017-08-08","conditions":["Acute Lymphoblastic Leukemia","B Acute Lymphoblastic Leukemia","Mixed Phenotype Acute Leukemia","T Acute Lymphoblastic Leukemia"],"enrollment":475,"completionDate":"2027-09-30"},{"nctId":"NCT01786265","phase":"PHASE2","title":"Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-02-05","conditions":["Prostate Adenocarcinoma","Recurrent Prostate Carcinoma"],"enrollment":310,"completionDate":"2027-02-01"},{"nctId":"NCT04947254","phase":"PHASE2","title":"Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-08-05","conditions":["Prostate Carcinoma","Stage IIC Prostate Cancer AJCC v8","Stage III Prostate Cancer AJCC v8","Stage IIIA Prostate Cancer AJCC v8","Stage IIIB Prostate Cancer AJCC v8","Stage IIIC Prostate Cancer AJCC v8","Stage IVA Prostate Cancer AJCC v8"],"enrollment":200,"completionDate":"2026-06-07"},{"nctId":"NCT04745949","phase":"PHASE2","title":"PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapy","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-05-10","conditions":["Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Lymphoma","Ann Arbor Stage II Primary Mediastinal (Thymic) Large B-Cell Lymphoma","Ann Arbor Stage III Primary Mediastinal (Thymic) Large B-Cell Lymphoma","Ann Arbor Stage IV Primary Mediastinal (Thymic) Large B-Cell Lymphoma"],"enrollment":31,"completionDate":"2027-08-03"},{"nctId":"NCT04872790","phase":"PHASE1","title":"Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia","status":"RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2022-09-02","conditions":["B Acute Lymphoblastic Leukemia","B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","Mixed Phenotype Acute Leukemia","Recurrent B Acute Lymphoblastic Leukemia","Recurrent Mixed Phenotype Acute Leukemia"],"enrollment":20,"completionDate":"2026-12-02"},{"nctId":"NCT03749018","phase":"PHASE2","title":"Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"David Bond, MD","startDate":"2019-01-02","conditions":["Aggressive Non-Hodgkin Lymphoma","Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma","Ann Arbor Stage II B-Cell Non-Hodgkin Lymphoma","Ann Arbor Stage II Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma","Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma","Ann Arbor Stage III Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma","Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma","Ann Arbor Stage IV Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma","Diffuse Large B-Cell Lymphoma","High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements","High Grade B-Cell Lymphoma, Not Otherwise Specified","Indolent Non-Hodgkin Lymphoma","Mediastinal B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma","Transformed Non-Hodgkin Lymphoma"],"enrollment":30,"completionDate":"2026-12-31"},{"nctId":"NCT04850495","phase":"PHASE1","title":"Zanubrutinib in Combination With R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma","status":"SUSPENDED","sponsor":"Yazeed Sawalha","startDate":"2021-11-16","conditions":["Diffuse Large B-Cell Lymphoma","Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma","Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma"],"enrollment":38,"completionDate":"2026-06-15"},{"nctId":"NCT04323956","phase":"PHASE1","title":"Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2020-06-15","conditions":["Ann Arbor Stage II Diffuse Large B-Cell Lymphoma","Ann Arbor Stage II Follicular Lymphoma","Ann Arbor Stage II Marginal Zone Lymphoma","Ann Arbor Stage III Diffuse Large B-Cell Lymphoma","Ann Arbor Stage III Follicular Lymphoma","Ann Arbor Stage III Marginal Zone Lymphoma","Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma","Ann Arbor Stage IV Follicular Lymphoma","Ann Arbor Stage IV Marginal Zone Lymphoma","Diffuse Large B-Cell Lymphoma","High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements","High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements","High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements","Indolent Non-Hodgkin Lymphoma"],"enrollment":50,"completionDate":"2028-05-16"},{"nctId":"NCT04734730","phase":"PHASE2","title":"Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2021-05-04","conditions":["Castration-Sensitive Prostate Carcinoma","Metastatic Prostate Adenocarcinoma","Stage IV Prostate Cancer AJCC v8","Stage IVA Prostate Cancer AJCC v8","Stage IVB Prostate Cancer AJCC v8"],"enrollment":70,"completionDate":"2027-08-23"},{"nctId":"NCT06470243","phase":"PHASE3","title":"Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2024-11-27","conditions":["Castration-Resistant Prostate Carcinoma","Stage IVB Prostate Cancer AJCC v8"],"enrollment":528,"completionDate":"2034-04"},{"nctId":"NCT04267887","phase":"PHASE2","title":"Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2020-05-11","conditions":["Castration-Sensitive Prostate Carcinoma","Metastatic Prostate Carcinoma","Stage IVB Prostate Cancer AJCC v8"],"enrollment":7,"completionDate":"2030-01-01"},{"nctId":"NCT07097363","phase":"PHASE2","title":"Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"University of Washington","startDate":"2025-12-07","conditions":["B-Cell Non-Hodgkin Lymphoma","Burkitt Lymphoma","Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements","High Grade B-Cell Lymphoma, Not Otherwise Specified","Primary Mediastinal Large B-Cell Lymphoma","T-Cell/Histiocyte-Rich Large B-Cell Lymphoma","Transformed B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma to Diffuse Large B-Ce"],"enrollment":18,"completionDate":"2030-05-31"},{"nctId":"NCT04151082","phase":"PHASE1,PHASE2","title":"High Dose Steroid Therapy (Prednisone or Methylprednisolone) for the Improvement of Symptoms of Late Radiation-Associated Lower Cranial Neuropathy in Oropharyngeal Cancer Survivors","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-10-16","conditions":["Cranial Nerve Disorder","Head and Neck Carcinoma","Oropharyngeal Carcinoma"],"enrollment":35,"completionDate":"2027-07-31"},{"nctId":"NCT03808610","phase":"PHASE1,PHASE2","title":"Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-04-03","conditions":["Recurrent B Acute Lymphoblastic Leukemia","Recurrent T Acute Lymphoblastic Leukemia","Refractory B Acute Lymphoblastic Leukemia","Refractory T Acute Lymphoblastic Leukemia"],"enrollment":50,"completionDate":"2026-12-31"},{"nctId":"NCT05689021","phase":"PHASE2","title":"CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-03-05","conditions":["Castration-Resistant Prostate Carcinoma","Metastatic Prostate Adenocarcinoma","Stage IVB Prostate Cancer AJCC v8"],"enrollment":8,"completionDate":"2026-03-31"},{"nctId":"NCT02949284","phase":"PHASE2","title":"Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rutgers, The State University of New Jersey","startDate":"2017-06-20","conditions":["Stage II Prostate Adenocarcinoma","Stage III Prostate Adenocarcinoma"],"enrollment":90,"completionDate":"2027-06"},{"nctId":"NCT00501826","phase":"PHASE2","title":"Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2007-07-11","conditions":["T Acute Lymphoblastic Leukemia","T Lymphoblastic Lymphoma"],"enrollment":160,"completionDate":"2026-10-31"},{"nctId":"NCT07072585","phase":"PHASE2,PHASE3","title":"Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)","status":"NOT_YET_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2026-06-28","conditions":["Stage II T Lymphoblastic Leukemia/Lymphoma","Stage III T Lymphoblastic Leukemia/Lymphoma","Stage IV T Lymphoblastic Leukemia/Lymphoma","T Acute Lymphoblastic Leukemia","T Lymphoblastic Lymphoma"],"enrollment":1708,"completionDate":"2035-09-01"},{"nctId":"NCT06378866","phase":"PHASE2","title":"Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-06-03","conditions":["Recurrent Castration-Sensitive Prostate Carcinoma","Recurrent Prostate Cancer","Castration-resistant Prostate Cancer","Biochemically Recurrent Prostate Carcinoma"],"enrollment":532,"completionDate":"2029-05-31"},{"nctId":"NCT05761171","phase":"PHASE2","title":"A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2024-01-08","conditions":["Recurrent Acute Leukemia of Ambiguous Lineage","Recurrent Acute Lymphoblastic Leukemia","Recurrent Acute Myeloid Leukemia Due to Lineage Switch From Acute Leukemia of Ambiguous Lineage","Recurrent Acute Myeloid Leukemia Due to Lineage Switch From B Acute Lymphoblastic Leukemia, KMT2A-Rearranged","Recurrent Acute Myeloid Leukemia Due to Lineage Switch From Mixed Phenotype Acute Leukemia","Recurrent Mixed Phenotype Acute Leukemia","Refractory Acute Leukemia of Ambiguous Lineage","Refractory Acute Lymphoblastic Leukemia","Refractory Acute Myeloid Leukemia Due to Lineage Switch From Acute Leukemia of Ambiguous Lineage","Refractory Acute Myeloid Leukemia Due to Lineage Switch From B Acute Lymphoblastic Leukemia, KMT2A-Rearranged","Refractory Acute Myeloid Leukemia Due to Lineage Switch From Mixed Phenotype Acute Leukemia","Refractory Mixed Phenotype Acute Leukemia"],"enrollment":78,"completionDate":"2027-12-31"},{"nctId":"NCT07278856","phase":"PHASE1","title":"Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas","status":"NOT_YET_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-04-27","conditions":["Follicular Helper T-Cell Lymphoma","Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type","Follicular Helper T-Cell Lymphoma, Follicular-Type","Follicular Helper T-Cell Lymphoma, Not Otherwise Specified","Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma","Peripheral T-Cell Lymphoma, Not Otherwise Specified"],"enrollment":20,"completionDate":"2027-03-31"},{"nctId":"NCT01424982","phase":"PHASE2","title":"Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2011-10-05","conditions":["Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive","Acute Lymphoblastic Leukemia","Adult Acute Lymphoblastic Leukemia in Complete Remission","B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive","Philadelphia Chromosome Positive","Untreated Adult Acute Lymphoblastic Leukemia"],"enrollment":88,"completionDate":"2027-10-31"},{"nctId":"NCT02112916","phase":"PHASE3","title":"Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-10-04","conditions":["Adult T Acute Lymphoblastic Leukemia","Ann Arbor Stage II Adult Lymphoblastic Lymphoma","Ann Arbor Stage II Childhood Lymphoblastic Lymphoma","Ann Arbor Stage III Adult Lymphoblastic Lymphoma","Ann Arbor Stage III Childhood Lymphoblastic Lymphoma","Ann Arbor Stage IV Adult Lymphoblastic Lymphoma","Ann Arbor Stage IV Childhood Lymphoblastic Lymphoma","Childhood T Acute Lymphoblastic Leukemia"],"enrollment":847,"completionDate":"2026-09-16"},{"nctId":"NCT02003222","phase":"PHASE3","title":"Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-05-19","conditions":["Acute Lymphoblastic Leukemia","B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative"],"enrollment":488,"completionDate":"2026-03-25"},{"nctId":"NCT02883049","phase":"PHASE3","title":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2012-02-29","conditions":["B Acute Lymphoblastic Leukemia","B Acute Lymphoblastic Leukemia, BCR-ABL1-Like","Central Nervous System Leukemia","Testicular Leukemia"],"enrollment":5949,"completionDate":"2026-10-03"},{"nctId":"NCT05600686","phase":"PHASE2","title":"Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma","status":"RECRUITING","sponsor":"Joseph Tuscano","startDate":"2023-05-24","conditions":["Double-Expressor Lymphoma","High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements","High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements","High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements"],"enrollment":24,"completionDate":"2028-02-01"},{"nctId":"NCT03113500","phase":"PHASE2","title":"Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2017-05-25","conditions":["Adult T-Cell Leukemia/Lymphoma","Anaplastic Large Cell Lymphoma, ALK-Negative","Anaplastic Large Cell Lymphoma, ALK-Positive","Angioimmunoblastic T-Cell Lymphoma","Ann Arbor Stage II Noncutaneous Anaplastic Large Cell Lymphoma","Ann Arbor Stage III Noncutaneous Anaplastic Large Cell Lymphoma","Ann Arbor Stage IV Noncutaneous Anaplastic Large Cell Lymphoma","Enteropathy-Associated T-Cell Lymphoma","Hepatosplenic T-Cell Lymphoma","Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma","Peripheral T-Cell Lymphoma, Not Otherwise Specified"],"enrollment":48,"completionDate":"2026-07-07"},{"nctId":"NCT02877303","phase":"PHASE2","title":"Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-11-01","conditions":["B Acute Lymphoblastic Leukemia","B Lymphoblastic Lymphoma"],"enrollment":80,"completionDate":"2026-11-01"},{"nctId":"NCT04978584","phase":"PHASE2","title":"Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-03-03","conditions":["Diffuse Large B-Cell Lymphoma"],"enrollment":62,"completionDate":"2027-01-16"},{"nctId":"NCT07220187","phase":"PHASE3","title":"Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMID Trial","status":"NOT_YET_RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2026-05-02","conditions":["Richter Syndrome","Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma","Transformed Small Lymphocytic Lymphoma to Diffuse Large B-Cell Lymphoma"],"enrollment":102,"completionDate":"2036-10"},{"nctId":"NCT03821792","phase":"PHASE2","title":"Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-07-22","conditions":["Metastatic Prostate Carcinoma","Prostate Adenocarcinoma","Prostate Carcinoma Metastatic in the Bone","Stage IV Prostate Cancer AJCC v8","Stage IVA Prostate Cancer AJCC v8","Stage IVB Prostate Cancer AJCC v8"],"enrollment":60,"completionDate":"2026-10-11"},{"nctId":"NCT03816332","phase":"PHASE1","title":"Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-11-08","conditions":["Clinical Stage III Cutaneous Melanoma AJCC v8","Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8","Clinical Stage IV Cutaneous Melanoma AJCC v8","Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8","Metastatic Basal Cell Carcinoma","Metastatic Melanoma","Metastatic Merkel Cell Carcinoma","Metastatic Skin Squamous Cell Carcinoma","Pathologic Stage III Cutaneous Melanoma AJCC v8","Pathologic Stage III Cutaneous Merkel Cell Carcinoma AJCC v8","Pathologic Stage IIIA Cutaneous Melanoma AJCC v8","Pathologic Stage IIIA Cutaneous Merkel Cell Carcinoma AJCC v8","Pathologic Stage IIIB Cutaneous Melanoma AJCC v8","Pathologic Stage IIIB Cutaneous Merkel Cell Carcinoma AJCC v8","Pathologic Stage IIIC Cutaneous Melanoma AJCC v8","Pathologic Stage IIID Cutaneous Melanoma AJCC v8","Pathologic Stage IV Cutaneous Melanoma AJCC v8","Pathologic Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8","Unresectable Basal Cell Carcinoma","Unresectable Melanoma","Unresectable Merkel Cell Carcinoma"],"enrollment":12,"completionDate":"2026-09-19"},{"nctId":"NCT05276492","phase":"PHASE1","title":"Decreasing Dosing Regimens of Abiraterone 500 mg in Men With Prostate Cancer to Find Lowest Recommended Dose.","status":"TERMINATED","sponsor":"University of Chicago","startDate":"2023-01-24","conditions":["Prostate Cancer","Prostate Adenocarcinoma","Prostate Neoplasm","Prostate Cancer Metastatic"],"enrollment":50,"completionDate":"2024-11-16"},{"nctId":"NCT06877429","phase":"","title":"Is the Diurnal Variation in Circulating Levels of Cortisol Reflected in Follicular Fluid of Preovulatory Follicles Close to Ovulation?","status":"NOT_YET_RECRUITING","sponsor":"ART Fertility Clinics LLC","startDate":"2025-12-30","conditions":["Healthy"],"enrollment":20,"completionDate":"2026-12"},{"nctId":"NCT07131943","phase":"NA","title":"Radiofrequency vs. Ultrasound Therapy for Shoulder Joint in Stroke Patients: A Comparative Clinical Trial","status":"RECRUITING","sponsor":"Cairo University","startDate":"2025-09-28","conditions":["Stroke ( 3 Months After Onset)","Stroke in Patients: New Tool to Evaluate the Impact in Their Life"],"enrollment":45,"completionDate":"2025-11-12"},{"nctId":"NCT03722303","phase":"EARLY_PHASE1","title":"Lipografting Versus Steroid Injections for Treatment of Carpal Tunnel Syndrome","status":"SUSPENDED","sponsor":"Columbia University","startDate":"2016-12-19","conditions":["Carpal Tunnel Syndrome"],"enrollment":100,"completionDate":"2026-12"},{"nctId":"NCT04479267","phase":"PHASE2","title":"Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Barbara Ann Karmanos Cancer Institute","startDate":"2020-08-21","conditions":["Diffuse Large B-Cell Lymphoma","High Grade B-Cell Lymphoma w/MYC & BCL2 or BCL6 Rearrangements","High Grade B-Cell Lymphoma w/MYC, BCL2 & BCL6 Rearrangements","Double Expressor Lymphoma","High-grade B-cell Lymphoma"],"enrollment":8,"completionDate":"2026-07-19"},{"nctId":"NCT00107198","phase":"PHASE2","title":"Treating Young Patients With Newly Diagnosed, Low Stage, Lymphocyte Predominant Hodgkin Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2006-01-02","conditions":["Ann Arbor Stage I Childhood Hodgkin Lymphoma","Ann Arbor Stage II Childhood Hodgkin Lymphoma","Childhood Nodular Lymphocyte Predominant B-Cell Lymphoma"],"enrollment":188,"completionDate":"2030-12-31"},{"nctId":"NCT03760835","phase":"PHASE4","title":"Congenital Adrenal Hyperplasia Once Daily Hydrocortisone Treatment","status":"RECRUITING","sponsor":"Federico II University","startDate":"2016-08-11","conditions":["Congenital Adrenal Hyperplasia"],"enrollment":150,"completionDate":"2027-12-31"},{"nctId":"NCT03678025","phase":"PHASE3","title":"Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2018-09-24","conditions":["Castration Levels of Testosterone","Metastatic Prostatic Adenocarcinoma","Stage IV Prostate Cancer AJCC v8","Stage IVA Prostate Cancer AJCC v8","Stage IVB Prostate Cancer AJCC v8"],"enrollment":1273,"completionDate":"2031-10-01"},{"nctId":"NCT04546399","phase":"PHASE2","title":"A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-12-17","conditions":["Down Syndrome","Recurrent B Acute Lymphoblastic Leukemia"],"enrollment":461,"completionDate":"2028-06-30"},{"nctId":"NCT00972478","phase":"PHASE1,PHASE2","title":"Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2010-11-15","conditions":["Ann Arbor Stage II Non-Hodgkin Lymphoma","Ann Arbor Stage III Non-Hodgkin Lymphoma","Ann Arbor Stage IV Non-Hodgkin Lymphoma"],"enrollment":83,"completionDate":"2026-03-06"},{"nctId":"NCT03505762","phase":"PHASE2","title":"Tailored Prednisone Reduction in Preventing Hyperglycemia in Participants With B-Cell Non-Hodgkin Lymphoma Receiving Combination Chemotherapy Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2018-07-19","conditions":["B-Cell Non-Hodgkin Lymphoma"],"enrollment":80,"completionDate":"2025-11"},{"nctId":"NCT05032183","phase":"PHASE1,PHASE2","title":"Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-02-17","conditions":["Recurrent Adult Lymphoblastic Lymphoma","Recurrent B Acute Lymphoblastic Leukemia","Recurrent T Acute Lymphoblastic Leukemia","Refractory B Acute Lymphoblastic Leukemia","Refractory Lymphoblastic Lymphoma","Refractory T Acute Lymphoblastic Leukemia"],"enrollment":4,"completionDate":"2024-07-31"},{"nctId":"NCT07111143","phase":"NA","title":"Nursing Interventions to Mitigate Climate Change-related Effects on Symptom Severity and Physical Capacity","status":"COMPLETED","sponsor":"Norther Private Collage of Nursing","startDate":"2024-09-01","conditions":["Asthma Exacerbations"],"enrollment":120,"completionDate":"2025-05-29"},{"nctId":"NCT03220022","phase":"PHASE1","title":"Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-03-16","conditions":["AIDS-Related Lymphoma","Ann Arbor Stage II Diffuse Large B-Cell Lymphoma","Ann Arbor Stage III Diffuse Large B-Cell Lymphoma","Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma"],"enrollment":46,"completionDate":"2026-07-16"},{"nctId":"NCT03951480","phase":"NA","title":"Care of AcromioClavicular Arthropathy in Manual Medicine Versus Corticosteroid Infiltration (ACAM)","status":"TERMINATED","sponsor":"Centre Hospitalier Departemental Vendee","startDate":"2020-11-24","conditions":["Acromioclavicular Arthropathy"],"enrollment":35,"completionDate":"2025-06-06"},{"nctId":"NCT04139304","phase":"EARLY_PHASE1","title":"A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma","status":"RECRUITING","sponsor":"AIDS Malignancy Consortium","startDate":"2021-05-24","conditions":["Plasmablastic Lymphoma","Ann Arbor Stage I Diffuse Large B-Cell Lymphoma","Ann Arbor Stage II Diffuse Large B-Cell Lymphoma","Ann Arbor Stage III Diffuse Large B-Cell Lymphoma","Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma"],"enrollment":15,"completionDate":"2030-07"},{"nctId":"NCT03742258","phase":"PHASE1","title":"Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2019-03-13","conditions":["Diffuse Large B-Cell Lymphoma","Diffuse Large B-Cell Lymphoma Activated B-Cell Type","Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type","Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements","High Grade B-Cell Lymphoma, Not Otherwise Specified","T-Cell/Histiocyte-Rich Large B-Cell Lymphoma"],"enrollment":12,"completionDate":"2024-02-08"},{"nctId":"NCT02420717","phase":"PHASE2","title":"Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-07-15","conditions":["Recurrent B Acute Lymphoblastic Leukemia","Recurrent Ph-Like Acute Lymphoblastic Leukemia","Refractory B Acute Lymphoblastic Leukemia","Refractory Ph-Like Acute Lymphoblastic Leukemia"],"enrollment":11,"completionDate":"2021-01-20"},{"nctId":"NCT04752163","phase":"PHASE1,PHASE2","title":"DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-03-25","conditions":["Hematopoietic and Lymphoid Cell Neoplasm","Recurrent Acute Lymphoblastic Leukemia","Recurrent Acute Myeloid Leukemia","Recurrent Chronic Myelomonocytic Leukemia","Recurrent Myelodysplastic Syndrome","Refractory Acute Lymphoblastic Leukemia","Refractory Acute Myeloid Leukemia","Refractory Chronic Myelomonocytic Leukemia","Refractory Myelodysplastic Syndrome"],"enrollment":17,"completionDate":"2023-11-08"},{"nctId":"NCT00408005","phase":"PHASE3","title":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2007-01-30","conditions":["T Acute Lymphoblastic Leukemia","T Lymphoblastic Lymphoma"],"enrollment":1895,"completionDate":"2025-03-31"},{"nctId":"NCT05367271","phase":"PHASE2,PHASE3","title":"The Efficacy of Botulinum Toxin vs. Corticosteroid for the Treatment of Refractory Plantar Fasciitis","status":"COMPLETED","sponsor":"Western Institute for Veterans Research","startDate":"2022-08-23","conditions":["Plantar Fasciitis"],"enrollment":62,"completionDate":"2024-09-13"},{"nctId":"NCT05479448","phase":"","title":"Predictive Factors for Treatment Response in Patients With Newly-diagnosed Polymyalgia Rheumatica and Giant Cell Arteritis","status":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2022-06-03","conditions":["Polymyalgia Rheumatica (PMR)","Giant Cell Arteritis (GCA)"],"enrollment":30,"completionDate":"2028-12"},{"nctId":"NCT06251180","phase":"PHASE1","title":"Phase Ib Study of Rocbrutinib in Combination with R-CHOP in Patients with Newly Diagnosed B-cell Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Guangzhou Lupeng Pharmaceutical Company LTD.","startDate":"2024-04-10","conditions":["B-cell Non-Hodgkin Lymphoma"],"enrollment":112,"completionDate":"2029-12-31"},{"nctId":"NCT06249191","phase":"PHASE1,PHASE2","title":"Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma","status":"RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2024-06-13","conditions":["Diffuse Large B-Cell Lymphoma","High Grade B-Cell Lymphoma"],"enrollment":30,"completionDate":"2027-04-01"},{"nctId":"NCT02828358","phase":"PHASE2","title":"Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-04-01","conditions":["Acute Leukemia of Ambiguous Lineage","B Acute Lymphoblastic Leukemia","Mixed Phenotype Acute Leukemia"],"enrollment":78,"completionDate":"2024-12-31"},{"nctId":"NCT03781700","phase":"PHASE4","title":"Evaluation of Cortisone Treatment in Children With Acute Facial Nerve Palsy","status":"RECRUITING","sponsor":"Dalarna County Council, Sweden","startDate":"2019-05-03","conditions":["Facial Palsy","Facial Nerve Diseases","Borrelia Infection of Central Nervous System","Bell Palsy"],"enrollment":500,"completionDate":"2026-12-31"},{"nctId":"NCT00390793","phase":"PHASE2","title":"Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-09-28","conditions":["Acute Lymphoblastic Leukemia","BCR-ABL1 Fusion Protein Expression","Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive","Philadelphia Chromosome Positive","Recurrent Acute Lymphoblastic Leukemia","t(9;22)"],"enrollment":107,"completionDate":"2024-02-02"},{"nctId":"NCT03379168","phase":"NA","title":"Efficacy of Micro-fragmented Adipose Tissue Injection for Knee Osteoarthritis.","status":"COMPLETED","sponsor":"Dustin L. Richter, MD","startDate":"2018-04-01","conditions":["Knee Osteoarthritis"],"enrollment":75,"completionDate":"2023-10-01"},{"nctId":"NCT06737445","phase":"NA","title":"Corticosteroid Injection, Extracorporeal Shock Wave Therapy, and Radiofrequency Ablation for Chronic Plantar Fasciitis:","status":"COMPLETED","sponsor":"Kars Harakani State Hospital","startDate":"2021-04-01","conditions":["Chronic Plantar Fasciitis"],"enrollment":49,"completionDate":"2023-02-01"},{"nctId":"NCT02807805","phase":"PHASE2","title":"Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mamta Parikh","startDate":"2016-10","conditions":["Metastatic Prostate Carcinoma","Recurrent Prostate Carcinoma","Stage IV Prostate Cancer"],"enrollment":37,"completionDate":"2025-12"},{"nctId":"NCT02196155","phase":"NA","title":"Botulinum Toxin A Versus Steroids for the Treatment of Chronic Plantar Fasciitis","status":"RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2016-07","conditions":["Plantar Fasciitis"],"enrollment":54,"completionDate":"2026-12"},{"nctId":"NCT06637384","phase":"PHASE4","title":"Effect of Hyaluronic Acid and Single Dose Corticosteroid Injection to Improve Wound Healing in Controlled Diabetic Patients Post Tooth Extraction.","status":"COMPLETED","sponsor":"Rimsha Rasheed","startDate":"2024-03-01","conditions":["Diabetes Mellitus","Wound Healing Delayed"],"enrollment":128,"completionDate":"2024-07-31"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral","formulation":"Tablet","formulations":[{"form":"TABLET","route":"ORAL","productName":"Cortisone Acetate"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000146287","MMSL":"4508","NDDF":"002146","UNII":"883WKN7W8X","VUID":"4017937","CHEBI":"CHEBI:3897","VANDF":"4017936","RXNORM":"21655","UMLSCUI":"C0056391","chemblId":"CHEMBL1650","ChEMBL_ID":"CHEMBL1650","KEGG_DRUG":"D00973","DRUGBANK_ID":"DB01380","PUBCHEM_CID":"5745","SNOMEDCT_US":"127382005","SECONDARY_CAS_RN":"53-06-5","MESH_DESCRIPTOR_UI":"D003348"},"formularyStatus":[],"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"present","companyName":"Merck","relationship":"Current Owner"}],"publicationCount":973,"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"recentPublications":[{"date":"2025","pmid":"41561040","title":"Effects of Lenvatinib treatment for advanced differentiated thyroid cancer on cortisol deficiency.","journal":"Frontiers in endocrinology"},{"date":"2026","pmid":"41411214","title":"Inhalation of N-Chlorotaurine Is an Effective Treatment of <italic>Aspergillus fumigatus</italic> Pneumonia in Mice.","journal":"Journal of innate immunity"},{"date":"2025 Nov 15","pmid":"41305402","title":"Invariant and Diverse NKT Cells Regulate Bacterial Clearance and Pathology in Chlamydial Genital Tract Infection in Mice.","journal":"Pathogens (Basel, Switzerland)"},{"date":"2025 Oct","pmid":"40913682","title":"Mineralocorticoid effects of fludrocortisone and hydrocortisone in primary adrenal insufficiency: EU-AIR patient data.","journal":"Journal of endocrinological investigation"},{"date":"2025 Dec 1","pmid":"40876212","title":"High-throughput suspect screening of priority hormone-disrupting chemicals in megacity aquatic ecosystems using a domain-specific database framework.","journal":"Water research"}],"companionDiagnostics":[],"genericManufacturers":12,"_genericFilersChecked":true,"genericManufacturerList":["Barr","Chartwell Molecular","Elkins Sinn","Everylife","Heather","Hikma Intl Pharms","Inwood Labs","Ivax Sub Teva Pharms","Purepac Pharm","Vitarine","Watson Labs","Whiteworth Town Plsn"],"status":"approved","companyName":"Merck","companyId":"","modality":"Small molecule","firstApprovalDate":"1950","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1950-06-13T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":""},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":"1950-06-13T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":"1950-06-13T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":null},{"country_code":"SA","regulator":"SFDA","status":"likely_approved","approval_date":"1950-06-13T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":"1950-06-13T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":"1950-06-13T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":null},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2024-06-05T00:00:00.000Z","mah":"CHARTWELL MOLECULAR","brand_name_local":null,"application_number":"ANDA080694"},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:31:52.801327+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}